vs

Side-by-side financial comparison of COGNEX CORP (CGNX) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

COGNEX CORP is the larger business by last-quarter revenue ($252.3M vs $197.9M, roughly 1.3× REPLIGEN CORP). COGNEX CORP runs the higher net margin — 12.9% vs 6.7%, a 6.2% gap on every dollar of revenue. On growth, REPLIGEN CORP posted the faster year-over-year revenue change (13.6% vs 9.9%). COGNEX CORP produced more free cash flow last quarter ($72.3M vs $17.6M). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (14.4% CAGR vs 9.4%).

Cognex Corporation is an American manufacturer of machine vision systems, software and sensors. Cognex is headquartered in Natick, Massachusetts, USA with offices in more than 20 countries.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

CGNX vs RGEN — Head-to-Head

Bigger by revenue
CGNX
CGNX
1.3× larger
CGNX
$252.3M
$197.9M
RGEN
Growing faster (revenue YoY)
RGEN
RGEN
+3.8% gap
RGEN
13.6%
9.9%
CGNX
Higher net margin
CGNX
CGNX
6.2% more per $
CGNX
12.9%
6.7%
RGEN
More free cash flow
CGNX
CGNX
$54.8M more FCF
CGNX
$72.3M
$17.6M
RGEN
Faster 2-yr revenue CAGR
RGEN
RGEN
Annualised
RGEN
14.4%
9.4%
CGNX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CGNX
CGNX
RGEN
RGEN
Revenue
$252.3M
$197.9M
Net Profit
$32.7M
$13.3M
Gross Margin
65.7%
52.5%
Operating Margin
14.0%
9.0%
Net Margin
12.9%
6.7%
Revenue YoY
9.9%
13.6%
Net Profit YoY
15.2%
143.9%
EPS (diluted)
$0.20
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CGNX
CGNX
RGEN
RGEN
Q4 25
$252.3M
$197.9M
Q3 25
$276.9M
$188.8M
Q2 25
$249.1M
$182.4M
Q1 25
$216.0M
$169.2M
Q4 24
$229.7M
$174.1M
Q3 24
$234.7M
$154.9M
Q2 24
$239.3M
$154.1M
Q1 24
$210.8M
$151.3M
Net Profit
CGNX
CGNX
RGEN
RGEN
Q4 25
$32.7M
$13.3M
Q3 25
$17.7M
$14.9M
Q2 25
$40.5M
$14.9M
Q1 25
$23.6M
$5.8M
Q4 24
$28.3M
$-30.3M
Q3 24
$29.6M
$-654.0K
Q2 24
$36.2M
$3.3M
Q1 24
$12.0M
$2.1M
Gross Margin
CGNX
CGNX
RGEN
RGEN
Q4 25
65.7%
52.5%
Q3 25
67.6%
53.2%
Q2 25
67.4%
50.0%
Q1 25
66.8%
53.6%
Q4 24
68.7%
26.1%
Q3 24
67.9%
50.0%
Q2 24
69.6%
49.8%
Q1 24
67.3%
49.5%
Operating Margin
CGNX
CGNX
RGEN
RGEN
Q4 25
14.0%
9.0%
Q3 25
20.9%
8.9%
Q2 25
17.4%
7.6%
Q1 25
12.1%
3.9%
Q4 24
13.4%
-17.7%
Q3 24
13.4%
-5.1%
Q2 24
16.1%
1.0%
Q1 24
6.7%
1.3%
Net Margin
CGNX
CGNX
RGEN
RGEN
Q4 25
12.9%
6.7%
Q3 25
6.4%
7.9%
Q2 25
16.3%
8.2%
Q1 25
10.9%
3.4%
Q4 24
12.3%
-17.4%
Q3 24
12.6%
-0.4%
Q2 24
15.1%
2.2%
Q1 24
5.7%
1.4%
EPS (diluted)
CGNX
CGNX
RGEN
RGEN
Q4 25
$0.20
$0.24
Q3 25
$0.10
$0.26
Q2 25
$0.24
$0.26
Q1 25
$0.14
$0.10
Q4 24
$0.17
$-0.55
Q3 24
$0.17
$-0.01
Q2 24
$0.21
$0.06
Q1 24
$0.07
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CGNX
CGNX
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$262.9M
$767.6M
Total DebtLower is stronger
$542.2M
Stockholders' EquityBook value
$1.5B
$2.1B
Total Assets
$2.0B
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CGNX
CGNX
RGEN
RGEN
Q4 25
$262.9M
$767.6M
Q3 25
$245.9M
$748.7M
Q2 25
$179.3M
$708.9M
Q1 25
$143.7M
$697.2M
Q4 24
$186.1M
$757.4M
Q3 24
$197.1M
$784.0M
Q2 24
$176.6M
$809.1M
Q1 24
$138.9M
$780.6M
Total Debt
CGNX
CGNX
RGEN
RGEN
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CGNX
CGNX
RGEN
RGEN
Q4 25
$1.5B
$2.1B
Q3 25
$1.5B
$2.1B
Q2 25
$1.5B
$2.1B
Q1 25
$1.4B
$2.0B
Q4 24
$1.5B
$2.0B
Q3 24
$1.6B
$2.0B
Q2 24
$1.5B
$2.0B
Q1 24
$1.5B
$2.0B
Total Assets
CGNX
CGNX
RGEN
RGEN
Q4 25
$2.0B
$2.9B
Q3 25
$2.0B
$2.9B
Q2 25
$2.0B
$2.9B
Q1 25
$1.9B
$2.9B
Q4 24
$2.0B
$2.8B
Q3 24
$2.1B
$2.8B
Q2 24
$2.0B
$2.9B
Q1 24
$2.0B
$2.8B
Debt / Equity
CGNX
CGNX
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CGNX
CGNX
RGEN
RGEN
Operating Cash FlowLast quarter
$74.9M
$25.7M
Free Cash FlowOCF − Capex
$72.3M
$17.6M
FCF MarginFCF / Revenue
28.7%
8.9%
Capex IntensityCapex / Revenue
1.0%
4.1%
Cash ConversionOCF / Net Profit
2.29×
1.93×
TTM Free Cash FlowTrailing 4 quarters
$236.8M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CGNX
CGNX
RGEN
RGEN
Q4 25
$74.9M
$25.7M
Q3 25
$87.5M
$48.1M
Q2 25
$42.6M
$28.6M
Q1 25
$40.5M
$15.0M
Q4 24
$51.4M
$39.2M
Q3 24
$56.3M
$49.3M
Q2 24
$27.8M
$42.2M
Q1 24
$13.6M
$44.7M
Free Cash Flow
CGNX
CGNX
RGEN
RGEN
Q4 25
$72.3M
$17.6M
Q3 25
$86.0M
$43.4M
Q2 25
$40.4M
$21.5M
Q1 25
$38.0M
$11.4M
Q4 24
$49.3M
$33.6M
Q3 24
$51.9M
$42.3M
Q2 24
$23.3M
$37.4M
Q1 24
$9.6M
$36.4M
FCF Margin
CGNX
CGNX
RGEN
RGEN
Q4 25
28.7%
8.9%
Q3 25
31.1%
23.0%
Q2 25
16.2%
11.8%
Q1 25
17.6%
6.8%
Q4 24
21.5%
19.3%
Q3 24
22.1%
27.3%
Q2 24
9.7%
24.3%
Q1 24
4.5%
24.0%
Capex Intensity
CGNX
CGNX
RGEN
RGEN
Q4 25
1.0%
4.1%
Q3 25
0.5%
2.5%
Q2 25
0.9%
3.9%
Q1 25
1.2%
2.1%
Q4 24
0.9%
3.2%
Q3 24
1.9%
4.5%
Q2 24
1.9%
3.1%
Q1 24
1.9%
5.5%
Cash Conversion
CGNX
CGNX
RGEN
RGEN
Q4 25
2.29×
1.93×
Q3 25
4.95×
3.23×
Q2 25
1.05×
1.92×
Q1 25
1.72×
2.57×
Q4 24
1.81×
Q3 24
1.90×
Q2 24
0.77×
12.70×
Q1 24
1.13×
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons